BACKGROUND: The aim of this study was to calculate the risk of metachronous colorectal cancers, to specify their characteristics and potential risk factors in a well-defined French population over a 27-year period. PATIENTS AND METHODS: The 10,801 patients who had colorectal cancers totalled 61,879 person-years of follow-up. The actuarial method was used to obtain crude metachronous colorectal cancer rates. Standardised incidence ratios (SIRs) were calculated. RESULTS: The cumulative rate of metachronous colorectal cancer was 1.8% at 5 years, 3.4% at 10 years and 7.2% at 20 years. The incidence of metachronous colorectal cancer following a first colorectal cancer was higher than expected (SIR: 1.5 [1.3-1.7] p<0.001). It remained greater throughout the study period, significantly only between the first and the fifth years following diagnosis (SIR: 1.9 [1.6-2.3] p<0.010). As compared to solitary cancers, metachronous cancers were diagnosed at earlier stages (23.5% versus 40.9% were stage I, p<0.001). None of the personal and tumour characteristics were predicting factors for the development of metachronous colorectal cancer. CONCLUSION: Patients with colorectal cancer are at greater risk of developing a metachronous colorectal cancer. Among them, no predicting factors for the development of metachronous tumours were found. Thus lifelong colonoscopic surveillance is needed.
BACKGROUND: The aim of this study was to calculate the risk of metachronous colorectal cancers, to specify their characteristics and potential risk factors in a well-defined French population over a 27-year period. PATIENTS AND METHODS: The 10,801 patients who had colorectal cancers totalled 61,879 person-years of follow-up. The actuarial method was used to obtain crude metachronous colorectal cancer rates. Standardised incidence ratios (SIRs) were calculated. RESULTS: The cumulative rate of metachronous colorectal cancer was 1.8% at 5 years, 3.4% at 10 years and 7.2% at 20 years. The incidence of metachronous colorectal cancer following a first colorectal cancer was higher than expected (SIR: 1.5 [1.3-1.7] p<0.001). It remained greater throughout the study period, significantly only between the first and the fifth years following diagnosis (SIR: 1.9 [1.6-2.3] p<0.010). As compared to solitary cancers, metachronous cancers were diagnosed at earlier stages (23.5% versus 40.9% were stage I, p<0.001). None of the personal and tumour characteristics were predicting factors for the development of metachronous colorectal cancer. CONCLUSION:Patients with colorectal cancer are at greater risk of developing a metachronous colorectal cancer. Among them, no predicting factors for the development of metachronous tumours were found. Thus lifelong colonoscopic surveillance is needed.
Authors: H Kamiyama; K Suzuki; T Maeda; K Koizumi; Y Miyaki; S Okada; Y J Kawamura; J K Samuelsson; S Alonso; F Konishi; M Perucho Journal: Oncogene Date: 2012-02-06 Impact factor: 9.867
Authors: Charles J Kahi; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas J Robertson; Douglas K Rex Journal: Am J Gastroenterol Date: 2016-02-12 Impact factor: 10.864
Authors: Matthew D Rutter; James East; Colin J Rees; Neil Cripps; James Docherty; Sunil Dolwani; Philip V Kaye; Kevin J Monahan; Marco R Novelli; Andrew Plumb; Brian P Saunders; Siwan Thomas-Gibson; Damian J M Tolan; Sophie Whyte; Stewart Bonnington; Alison Scope; Ruth Wong; Barbara Hibbert; John Marsh; Billie Moores; Amanda Cross; Linda Sharp Journal: Gut Date: 2019-11-27 Impact factor: 31.793
Authors: Harindra Jayasekara; Jeanette C Reece; Daniel D Buchanan; Christophe Rosty; S Ghazaleh Dashti; Driss Ait Ouakrim; Ingrid M Winship; Finlay A Macrae; Alex Boussioutas; Graham G Giles; Dennis J Ahnen; Jan Lowery; Graham Casey; Robert W Haile; Steven Gallinger; Loic Le Marchand; Polly A Newcomb; Noralane M Lindor; John L Hopper; Susan Parry; Mark A Jenkins; Aung Ko Win Journal: Int J Cancer Date: 2016-05-09 Impact factor: 7.316